Metformin is another popular and effective option, and according to the American Diabetes Association, DPP-4 inhibitors, SGLT2 inhibitors, sulfonylureas, and thiazolidinediones are other viable alternatives
While these warnings primarily target compounded injectable products , the same regulatory principles apply to patches making GLP-1 claims
Some individuals gain weight while on both medications due to the combined effect of steroid-induced appetite increase and reduced metabolic rate
FDA Telehealth Warning Letters In early March 2026, the FDA reportedly issued warning letters to multiple telehealth companies regarding compounded GLP-1 marketing practices, with concerns including misleading marketing claims, implications of equivalence with FDA-approved drugs, and obscuring product sourcing
The dual nature of type I and type II interferons
However, the evidence base is too small and too old to make confident safety claims